Factors involved in patient choice of oral or vaginal treatment for vulvovaginal candidiasis

Patient Preference and Adherence

Volumn 8, Issue , 2013, Pages 31-34

  Sobel, Jack D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antifungal drugs; Antimycotics; Candida vaginitis; Vulvovaginal candidiasis

Indexed keywords

ANTIFUNGAL AGENT; BUTOCONAZOLE; CLOTRIMAZOLE; FLUCONAZOLE; IMIDAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NON PRESCRIPTION DRUG; NYSTATIN; STEROID; TERCONAZOLE; TIOCONAZOLE; TRIAZOLE DERIVATIVE; GENERIC DRUG;

BURNING SENSATION; CREAM; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HUMAN; LIVER TOXICITY; PATIENT PREFERENCE; PRESCRIPTION; RASH; REVIEW; SINGLE DRUG DOSE; SKIN IRRITATION; STEVENS JOHNSON SYNDROME; SUPPOSITORY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VAGINA CANDIDIASIS; ARTICLE; CLINICAL COMPETENCE; CLINICAL PRACTICE; DIAGNOSTIC TEST; DOCTOR PATIENT RELATION; DRUG ADMINISTRATION ROUTE; DRUG CHOICE; DRUG DOSAGE FORM COMPARISON; DRUG POTENCY; DRUG QUALITY; DRUG RESEARCH; HEALTH INSURANCE; INTERMETHOD COMPARISON; NONHUMAN; PATIENT DECISION MAKING; POINT OF CARE TESTING; TREATMENT OUTCOME;

EID: 84890477275     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S38984     Document Type: Review

References (18)

1. Ferris DG, Nyirjesy P, Sobel JD, Soper D, Pavletic A, Litaker MS. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol. 2002;99:419-425.
2. Sobel JD, Subramanian C, Foxman B, Fairfax M, Gygax SE. Mixed vaginitis - more than coinfection and with therapeutic implications. Curr Infect Dis Rep. 2013;15:104-108.
3. Mendling W, Brasch J. German Society for Gynecology and Obstetrics, Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infect immunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society. Mycoses. 2012;55 Suppl 3:1-13.
4. [No authors listed]. National guideline for the management of vulvovaginal candidiasis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Sex Transm Infect. 1999;75 Suppl 1:S19-S20.
5. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-535.
6. Reef SE, Levine WC, McNeil MM, et al. Treatment options for vulvovaginal candidiasis, 1993. Clin Infect Dis. 1995;20 Suppl 1: S80-S90.
7. British Association for Sexual Health and HIV. United Kingdom National Guideline on the Management of Vulvovaginal Candidiasis (2007). Available from: http://www.bashh.org/documents/1798.pdf. Accessed December 4, 2008.
8. Workowski KA, Berman S; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59:1-110.
9. Young GL, Jewell D. Topical treatment for vaginal candidiasis (thrush) in pregnancy. Cochrane Database Syst Rev. 2001;4:CD000225.
10. Sobel JD, Kapernick PS, Zervos M, et al. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol. 2001;185:363-369.
11. Watson MC, Grimshaw JM, Bond CM, Mollison J, Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev. 2001;4:CD002845.
12. Sobel JD, Brooker D, Stein GE, et al. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group. Am J Obstet Gynecol. 1995;172:1263-1268.
13. Sobel JD, Faro S, Force RW, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998;178:203-211.
14. Houang ET, Chappatte O, Byrne D, Macrae PV, Thorpe JE. Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis. Antimicrob Agents Chemother. 1990;34:909-910.
15. Mølgaard-Nielsen D, Pasternak B, Hviid A. Use of oral fluconazole during pregnancy and the risk of birth defects. N Engl J Med. 2013;369: 830-839.
16. Nørgaard M, Pedersen L, Gislum M, et al. Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study. J Antimicrob Chemother. 2008;62:172-176.
17. Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004;351: 876-883.
18. Donders G, Bellen G, Byttebier G, et al. Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). Am J Obstet Gynecol. 2008;199:613. e1-e9.